A global leader in oncolytic immunotherapeutics – targeting, attacking, and eradicating cancer

Our Story

SillaJen Biotherapeutics, Inc. is a clinical-stage company focused on developing and commercializing oncolytic immunotherapy products for cancer. Our lead product Pexa-Vec is being evaluated in a multinational Phase 3 clinical trial (PHOCUS) in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

SillaJen Biotherapeutics, Inc. was formerly known as Jennerex, Inc.; we were acquired in 2014 by SillaJen, Inc., a privately-held Korean biotechnology company, and subsequently changed our name to reflect the new ownership. SillaJen Biotherapeutics is located in San Francisco and is responsible for manufacturing, regulatory affairs, alliance management, clinical operations and accounting for clinical trials. The parent company has responsibility for finance, management, legal operations and R&D and has offices in Busan and Seoul, Korea.

Company History

  • January, 2016 – SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer.phocus
  • April, 2015 – SillaJen Announces Agreement with the FDA for a Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
  • March, 2014 – SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics for cancer.
  • December, 2011 – Jennerex completes Phase 2a study of intratumoral injection of Pexa-Vec in patients with hepatocellular carcinoma (HEP007).
  • July, 2007 – Jennerex completes a Phase 1 Study to Evaluate the Safety and efficacy of JX-594 (Pexa-Vec) in patients with hepatocellular carcinoma (HEP001).
  • May, 2006 – Jennerex and SillaJen agreement to collaborate on research and development of oncolytic viruses to treat cancer.
  • March, 2006 – SillaJen, Inc. is established.
    SillaJen Logo (high res)
  • April, 2004 – Jennerex files Investigational New Drug (IND) Application.